Fluorescent Markers for Blinding Eye Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments and diagnostic methods for blinding eye diseases such as age-related macular degeneration (AMD) and reticular pseudodrusen (RPD), which are associated with significant vision loss and cardiovascular mortality, with existing therapies being inadequate.
Innovation Solution
A method involving the administration of a test compound to an animal model with fluorescent markers to induce ocular tissue atrophy, followed by fluorescence pattern comparison to identify potential therapeutic compounds, and the use of compounds like methotrexate or Formula I for treating AMD and RPD, along with diagnostic techniques like delayed near-infrared analysis (DNIRA) to assess disease presence and treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used for AMD and RPD, then treatment options are limited, but disease progression and vision loss continue
Solution Approach 1:
The patent employs a high-throughput screening approach that pre-tests multiple candidate compounds against disease markers and cellular models before clinical application. This preliminary identification and validation of effective compounds (such as methotrexate and bindarit) ensures reliable treatment options are established in advance, addressing the lack of effective therapies while maintaining versatility through multiple screened candidates.
2Measurement precision
If diagnostic methods are improved for early detection, then disease presence can be identified, but current diagnostic capabilities are insufficient
Solution Approach 1:
The patent utilizes fluorescent markers and near-infrared imaging technology as intermediary tools to detect disease presence and treatment response. These intermediaries translate biological changes (such as compound uptake by cells or disease marker expression) into measurable optical signals, enabling precise non-invasive detection of AMD and RPD that overcomes current diagnostic limitations.
3Productivity
If compound screening is performed using animal models with fluorescent markers, then effective therapeutic compounds can be identified, but the complexity of the screening process increases
Solution Approach 1:
The patent replaces complex manual screening procedures with automated near-infrared fluorescence imaging systems. The fluorescent markers integrated into the animal models allow automated detection and quantification of compound effects, substituting mechanical and visual assessment with optical detection systems that increase productivity while managing complexity through standardization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the identification of effective therapeutic compounds and diagnostic methods that can treat and prevent AMD and RPD, improving vision outcomes and addressing the current treatment gaps for these diseases.
Implementation Method 1
exposing the eye to light having a wavelength and intensity effective to cause the fluorescent compound to fluoresce
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).